New hypertension drug shows promise in early trial

NCT ID NCT00562549

Completed Disease control Sponsor: Retension Pharmaceuticals. Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called SLx-2101 in 26 adults with moderate to severe high blood pressure. Participants took the pill once daily for up to 12 days to see how well it lowers blood pressure and if it is safe. The goal is to find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SLx-2101
What this could lead to: If it works, this could point toward a new daily pill to help control high blood pressure.
What could go wrong: This is a small, early-phase trial with only 26 people and short treatment duration. The drug may not lower blood pressure enough or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, CB2 2QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.